BCMA CART + CD19 CART
BiologicalBCMA CART + CD19 CART
NCT Number: NCT06681337
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Early Phase 1
This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of combination therapy for refractory lupus nephritis using universal CAR-T cells targeting BCMA and CD19.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BCMA CART + CD19 CART
Time frame: Within 6 months after BCMA CART and CD19 CART infusion
The total number, incidence, and severity of AE
Time frame: At 6 months after BCMA CART and CD19 CART infusion
Complete response (CR) was defined as serum creatinine ≤ 1.2 mg/dl or ≤ 125% of baseline value, and urine protein/creatinine ratio < 0.5 or 24-hour urine protein quantification < 0.5 g, and prednisone dose reduction to ≤ 10 mg/d (or equivalent dose). Partial response (PR) was defined as if both serum creatinine and urine protein/creatinine ratio (or 24-hour urine protein quantification) were abnormal before treatment, both items improved by > 30% after treatment, without other indicators of deterioration; if only urine protein/creatinine ratio (or 24-hour urine protein quantification) was abnormal before treatment, the improvement was > 50% after treatment.
Time frame: Within 3 months after BCMA CART and CD19 CART infusion
Changes and duration of CAR gene copy number and CAR-T cell number in peripheral blood after BCMA CART and CD19 CART infusion
Contact information is provided by the study sponsor or research team.
Bioray Laboratories
Industry
A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07721363
Autoimmune Diseases, Connective Tissue Diseases
Paris, France
View Trial DetailsNCT07675291
Autoimmune Diseases, Connective Tissue Diseases
View Trial DetailsNCT07570862
Autoimmune Diseases, Connective Tissue Diseases
View Trial DetailsNCT07505576
Autoimmune Diseases, Connective Tissue Diseases
View Trial Details